🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Would love to do Journal Club on RENAL-AF trial with Drs Granger and Pokorney and with my treasured colleagues and Steering Committee members Wolfgang C. Winkelmayer Crystal Gadegbeku Kenneth Mahaffey. Joel M. Topf, MD FACP - if you recruit 2 or more patients by Aug 31, we’ll commit to September!

Mixed data on testosterone and CV risk. Will have to wait 5 years for results of the FDA-mandated TRAVERSE trial: 6,000 patients with low testosterone and CV disease, evaluating testosterone use for MACE. AHAMeetings #AHA18

High prevalence of sexual dysfunction in patients with ICDs. AHAMeetings #AHA18 #HeartFailure #ICD #Defibrillator

Understudied patient population with a critical clinical question.

#RENAL-AF. First randomized data of OAC in patients with AF and end stage renal disease.

Great SURF case.

Power limited by sample size. Bleeding safety was primary endpoint. CV death secondary endpoint so would not focus on that. Only 1 ICH in each arm. Major/clinically relevant non-major bleeding rates similar in both arms. Apixaban seems reasonable. PK/PD data coming. #RENALAF

AHA National CIED Infection Initiative. Dr. Roger Carrillo sharing a touching patient story/cautionary tale about defibrillator infection. #Treat2BeatCIEDInfection

⁦Kenneth Ellenbogen⁩ ⁦⁦Sean Pokorney⁩ staring our joint session on #managing #afib ⁦Duke University School of Medicine⁩ ⁦Duke Cardiology⁩ ⁦Heart Rhythm Society⁩ ⁦TulaneTRIAD⁩ #hrs2022